Polymerizable surfactants and their use as device forming comonomers

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,377,464
App. No.: 13/405,604
Granted: Feb 19, 2013
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Claims (6)

1. An ophthalmic device comprising:

a polymerized comonomer mixture comprising at least one polymerizable surfactant selected from the group consisting of a poloxamer di(meth)acrylate, a reverse poloxamer di(meth)acrylate, a poloxamine di(meth)acrylate, a reverse poloxamine di(meth)acrylate and mixtures thereof, wherein the at least one polymerizable surfactant is present in the comonomer mixture prior to polymerization in an amount of about 0.1 to about 4.9 weight percent, and further wherein the ophthalmic device is a contact lens, an intraocular lens or a corneal implant, wherein the ophthalmic device has a water content of from about 20 to about 90 weight percent.

2. A hydrogel contact lens comprising:

a polymerized comonomer mixture comprising at least one polymerizable surfactant selected from the group consisting of a poloxamer di(meth)acrylate, a reverse poloxamer di(meth)acrylate, a poloxamine di(meth)acrylate, a reverse poloxamine di(meth)acrylate and mixtures thereof, wherein the at least one polymerizable surfactant is present in the comonomer mixture prior to polymerization in an amount of about 0.1 to about 4.9 weight percent, and further wherein the ophthalmic device is a contact lens, an intraocular lens or a conical implant, wherein the ophthalmic device has a modulus from about 20 g/mm 2 to about 150 g/mm 2 .

3. A hydrogel contact lens comprising:

a polymerized comonomer mixture comprising at least one polymerizable surfactant selected from the group consisting of a poloxamer di(meth)acrylate, a reverse poloxamer di(meth)acrylate, a poloxamine di(meth)acrylate, a reverse poloxamine di(meth)acrylate and mixtures thereof, wherein the at least one polymerizable surfactant is present in the comonomer mixture prior to polymerization in an amount of about 0.1 to about 4.9 weight percent, and further wherein the ophthalmic device is a contact lens, an intraocular lens or a corneal implant, wherein the ophthalmic device has a modulus of from about 30 g/mm 2 to about 100 g/mm 2 .

Assignments (24)

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED

Reel/Frame 073637/0001 →

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.

Reel/Frame 073637/0126 →

RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025

From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT

To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.

Reel/Frame 073654/0242 →

ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025

From: CITIBANK, N.A., AS RESIGNING AGENT

To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT

Reel/Frame 072469/0091 →

RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025

From: BARCLAYS BANK PLC, AS COLLATERAL AGENT

To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.

Reel/Frame 070778/0199 →

PATENT SECURITY AGREEMENT Recorded Oct 4, 2023

From: BAUSCH & LOMB INCORPORATED

To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT

Reel/Frame 065120/0086 →

OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022